• Immunic flagged new Phase 2 CALLIPER open-label extension results for vidofludimus calcium in progressive multiple sclerosis.
• Data will be presented Oct. 21-23 at MSToronto2026, a joint ACTRIMS-ECTRIMS meeting; abstracts will be published online.
• Extension follow-up favored continuous treatment on disability outcomes, with low discontinuation rates through week 48.
• Separate analyses linked reduced EBV-related immune activity to better cognitive performance, supporting further study in progressive MS.
• Preclinical work suggested Nurr1-dependent neuronal survival effects, reinforcing a neuroprotective rationale alongside the drug’s anti-inflammatory profile.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2411806_en) on October 07, 2026, and is solely responsible for the information contained therein.